Search clinical trials for: Genvoya®

Total 13658 results

Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

HIV-1 Infection

United States, France, Austria, Germany
Fundacion SEIMC-GESIDA
Merck Sharp & Dohme LLC

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression (GENIS)

HIV Infections | Severe Immunosuppression

Spain
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
Gilead Sciences

Completed

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

HIV-1 Infection

Spain, France, United States, Germany, Italy
Gilead Sciences

Completed

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

HIV Infections | HIV

United States, Netherlands, Spain, Mexico, France, Thailand, Australia, United Kingdom, Dominican Republic
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
Gilead Sciences

Completed

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

HIV Infections | HIV

Canada, United States, Spain, Puerto Rico, France, Switzerland, Australia, Germany, United Kingdom, Sweden, Brazil, Austria, Thailand, Netherlands, Belgium, Dominican Republic, Portugal, Italy, Denmark, Mexico
Gilead Sciences

Completed

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

HIV

United States, South Africa
Gilead Sciences

Completed

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

HIV | HBV

United States, Canada, Japan
University of California, Los Angeles
Tulane University; Los Angeles LGBT Center

Active, not recruiting

Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

Human Immunodeficiency Virus

United States
Gilead Sciences

Active, not recruiting

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, Uganda, South Africa, Zimbabwe
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
Gilead Sciences

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

HIV-1 Infection

Spain, United Kingdom, France, Germany, United States, Italy
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, United Kingdom, Sweden, France, Puerto Rico, Netherlands, Italy, Portugal, Canada, Mexico, Dominican Republic
Gilead Sciences

Completed

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (Co-STARs)

HIV-1 Infection | HCV Infection

United States, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, Spain, Switzerland, Canada, Thailand, Puerto Rico, Australia, Austria, Belgium, Italy, Japan, United Kingdom
Gilead Sciences

Completed

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV

United States, Thailand, Uganda, Dominican Republic, Russian Federation
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. (PEP2)

HIV Infections

United States
Groupe d'Etude sur le Risque d'Exposition des Soignants...
Gilead Sciences

Completed

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

HIV Risk

France
Henry M. Jackson Foundation for the Advancement...
Gilead Sciences

Withdrawn

Antiretroviral Therapy for Acute HIV Infection

HIV Infections

Uganda
Ege University

Completed

Different Types of Electrostimulation Probes During IONM

Thyroid Diseases
Johns Hopkins University
Gilead Sciences

Completed

Analysis of Crushed and Whole Tablet Genvoya

Healthy Volunteers

United States
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

HIV Infections

United States
Dong-A ST Co., Ltd.

Completed

A Study to Demonstrate the Efficacy and Safety of Motilitone®

Functional Dyspepsia

Korea, Republic of
Galderma R&D

Completed

Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis

Atopic Dermatitis

Philippines, China
Chong Kun Dang Pharmaceutical

Completed

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

Healthy

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immune Response of Different Pediatric Combination Vaccines.

Pertussis | Diphtheria | Polio

United States
Chung-Ang University Hosptial, Chung-Ang University...

Unknown

A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia

Functional Dyspepsia

Korea, Republic of
Amir Azarpazhooh
Institut Straumann AG

Completed

Effect of Emdogain® on Soft Tissue Wound Healing

Periodontal Inflammation | Crown Lengthening

Canada
Novartis Pharmaceuticals

Completed

Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
Guerbet

Completed

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors (REMIND)

Primary Brain Tumor

Colombia, Korea, Republic of, United States, Mexico
University of Miami
BSN Medical Inc

Recruiting

VLU Dressing Study

Venous Leg Ulcer

United States
Sanofi Pasteur, a Sanofi Company

Completed

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

Pertussis

United States
Coopervision, Inc.

Completed

Clinical Evaluation of Biofinity Multifocal Compared With Air Optix Aqua Multifocal and With PureVision Multifocal (INNOVATION)

Presbyopia
Tufts University

Completed

Comparison of Post Tooth Extraction Healing Using Different Xenograft Materials

Alveolar Bone Loss

United States
Assistance Publique Hopitaux De Marseille

Completed

Clinical Evaluation of the Treatment of Intellectual Metastases by Radiosurgery Gamma Knife by Means of a Support System by Mask. (Mask)

Lung Cancer | Brain Metastases

France
University Hospital, Caen

Completed

Incidence of Dual Mobility Polyethylene Wear in Total Hip Prosthesis. Randomised Study Versus Fixed Insert by Radiostereometric Analysis. (DOUMOB)

Total Hip Replacement
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer

Cystic Fibrosis

Czechia, Moldova, Republic of, Slovakia
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Global Kinetics Corporation

Terminated

Utilization of Target Ranges to Treat Parkinson's Disease With the PKG (TARGET-PD)

Parkinson Disease

United States
Global Kinetics Corporation

Withdrawn

Utilization of Target Ranges to Treat Persons With Parkinson's Disease by Objective Measurement Using the PKG (TARGET-PwP)

Parkinson Disease
nthalmic Pty Ltd
Brighten Optix Corporation

Recruiting

S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Myopia

India, Spain, China
Lument AB

Terminated

A Randomized, Controlled Trial to Evaluate CT Image Quality Lumentin® 44

Subjects Referred to CT-examination of the Abdomen

Sweden
CereVasc Inc
AlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...

Terminated

Pilot Study to Evaluate the CereVasc® eShunt® System in the Treatment of Communicating Hydrocephalus

Hydrocephalus | Hydrocephalus, Communicating

United States
University of Baghdad

Completed

Evaluating Implant Stability Using Three Devices Osstell®, Periotest® and AnyCheck®

Edentulous Alveolar Ridge

Iraq
Novo Nordisk A/S

Completed

A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects

Healthy | Growth Disorder

United States
Guangzhou Institute of Respiratory Disease

Completed

Carbon Dioxide Rebreathing During Exercise Assisted by Non-invasive Ventilation

Pulmonary Disease, Chronic Obstructive

China
W.L.Gore & Associates

Active, not recruiting

GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry

Aortic Diseases | Aortic Aneurysm, Thoracic | Penetrating Ulcer | Descending Thoracic Aortic Dissection | Aorta Thoracic; Traumatic Rupture

France

3

Subscribe